Inhibition of factor XIIa, a new approach in management of thrombosis

Annals of Translational Medicine

Volumn 3, Issue , 2015, Pages

  Dorgalaleh, Akbar ^a,b   Hosseini, Maryam Sadat ^b   Mobaraki, Rashideh Naseri ^a   Alizadeh, Shaban ^b   Hosseini, Soudabeh ^a   Tabibian, Shadi ^b   Shamsizadeh, Morteza ^c   Moghaddam, Esmaeil Saneei ^d   Khosravi, Sohila ^d   Rahimizadeh, Aziz ^d  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHROUD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85015471385     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.02.14     Document Type: Editorial

References (7)

1. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol 2012;25:235-42.
2. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009;23:225-9.
3. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914-8.
4. Björkqvist J, Nickel KF, Stavrou E, et al. In vivo activation and functions of the protease factor XII. Thromb Haemost 2014;112:868-75.
5. Gailani D, Renné T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost 2007;5:1106-12.
6. Kenne E, Renné T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discov Today 2014;19:1459-64.
7. Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014;6:222ra17.